Readily Diagnostics
PrivateLast Round
VC Round
Oct 30, 2024
Total Funding Raised
$930,000
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Readily Diagnostics is a medical technology company that develops rapid, instrument-free molecular diagnostic tests for infectious diseases using padlock probe technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Readily Diagnostics Comparables
Compare Readily Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GRIP Molecular Technologies | 74% | |
| OraSure Technologies Inc | 71% | |
| Fuse Diagnostics | 71% |
Readily Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 30, 2024 | ||||
| Grant | Sep 4, 2024 | ||||
| Seed | Aug 2, 2023 |
Readily Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Uppsala Innovation Centre | Seed |
| European Regional Development Fund | Grant |
| Almi Invest AB | Seed, VC Round |
| Länsförsäkringar Uppsala | VC Round |
| Bio-X Accelerate Program | Grant |
| Uppsala University Invest | Seed, VC Round |
| Kjell och Märta Beijers Stiftelse | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 66% MoM, reaching 2.3K.
- Jan 13, 2025
Grew 67% QoQ from 6 to 10 employees.
Recent news
Latest coverage and updates
- is_developingSep 2, 2026
Readily Diagnostics AB is developing affordable point-of-care test for chlamydia, gonorrhea and trichomoniasis on Aug 24th '26.
- receives_financingAug 27, 2026
Readily Diagnostics AB received financing of $970K in grant on Aug 27th '26.
- is_developingAug 27, 2026
Readily Diagnostics AB is developing point-of-care platform on Jul 1st '26.
- is_developingAug 27, 2026
Readily Diagnostics AB is developing affordable test for the world's most common sexually transmitted infections on Aug 27th '26.
Readily Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Readily Diagnostics's valuation, stock price, and market status.
Is Readily Diagnostics a public or private company?
Readily Diagnostics is a private company.
What is the current stock price of Readily Diagnostics?
Readily Diagnostics is a private company with no public stock price. Caplight tracks Readily Diagnostics's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Readily Diagnostics worth (valuation)?
Valuation information for Readily Diagnostics is not publicly available.
Can I buy Readily Diagnostics stock?
Readily Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Readily Diagnostics's last funding round?
Readily Diagnostics's most recent funding round was VC Round on October 30, 2024.
Who are the main investors in Readily Diagnostics?
Key investors in Readily Diagnostics include Uppsala Innovation Centre, European Regional Development Fund, Almi Invest AB, Länsförsäkringar Uppsala, Bio-X Accelerate Program.
Will Readily Diagnostics IPO soon?
No public IPO plans have been announced for Readily Diagnostics.
How can I track Readily Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Readily Diagnostics's secondary market activity and sign up for updates.